Open an account

Korro Bio

KRRO · NASDAQ

$9.44+$0.53 (+5.95%)TodayMarket closed ·
Prev close $8.91

About KRRO

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company is headquartered in Cambridge, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2019-10-03. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.

Employees
58
Headquarters
Cambridge, Massachusetts
Listed
Oct 3, 2019
Sector
Health Care
Industry
Biotechnology
Website
korrobio.com

KRRO key statistics

Market cap
139.01M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
176.07K
Volume
235.05K
Open price
$8.92
High today
$9.63
Low today
$8.92
52 Week high
$48.70
52 Week low
$5.20

Korro Bio (KRRO) at a glance

As of Oct 20, 2026, Korro Bio (KRRO) shares are priced at $9.44, giving the company a market cap of 139.01M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $8.92 and $9.63. The current price is 5.8% above the day's low and 2.0% below its high.

Volume so far is 235.05K shares, above the average of 176.07K shares a day.

Over the past year Korro Bio has ranged from $5.20 to $48.70, and now sits 10% of the way up that range.

Korro Bio met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$1.07 per share against an estimate of -$1.48.

The average analyst price target is $20.40, 116.1% above the current price, from 11 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

82%of 11 analyst ratings say Buy
  • Buy81.8%
  • Hold18.2%
  • Sell0.0%
Price target · 13 analystsAvg $20.40
Low
$10.10
Now
$9.44
High
$31.50

KRRO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 17.0% on average.

  1. Q3 FY24: reported -$2.26 per share against an estimate of -$2.66
  2. Q4 FY24: reported -$2.26 per share against an estimate of -$2.53
  3. Q1 FY25: reported -$2.49 per share against an estimate of -$2.66
  4. Q2 FY25: reported -$2.74 per share against an estimate of -$2.62
  5. Q3 FY25: reported -$1.92 per share against an estimate of -$2.65
  6. Q4 FY25: reported -$1.65 per share against an estimate of -$2.11
  7. Q1 FY26: reported -$1.69 per share against an estimate of -$1.88
  8. Q2 FY26: reported -$1.07 per share against an estimate of -$1.48

KRRO news

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Vandana Singh

    Korro Bio Early Trial Results Fall Short; Stock Hits New Low

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Dow Dips Over 400 Points; JD.com Posts Upbeat Q3 Results

  • Avi Kapoor

    Nasdaq Down Over 150 Points; Disney Shares Fall After Q4 Results

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releaseGlobe Newswire

    Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

  • Avi Kapoor

    United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday

Similar companies

Companies in the same industry as Korro Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.